David Feltquate

David Feltquate currently serves as Chief Medical Officer at iTeos Therapeutics, a position held since August 2024, after previously holding the same title at Palleon Pharmaceuticals from June 2021 to July 2024. Prior to this, David Feltquate worked at Novartis from November 2019 to June 2021, leading the Precision Medicine Leadership Team and serving as Global Head of the Hematology Disease Unit. Earlier experience includes significant roles at Bristol-Myers Squibb, where David Feltquate was Head of Early Clinical Development and Vice President of Development Immuno-Oncology. Educational credentials include a Doctor of Medicine (MD) and a Doctor of Philosophy (PhD) in Immunology from UMass Chan Medical School, as well as a Bachelor's degree in Biology from the Massachusetts Institute of Technology.